News & Analysis on Clinical Trial Services & Contract Research And Development
The Tufts Center for the Study of Drug Development is out with a new study claiming that the average cost of bringing a new drug to market is around $2.6bn, though some are saying that number seems inflated.
UK researchers working with GSK say a newly identified immune cell communication mechanism could explain why some drugs don’t work and drive development of smaller, large molecule meds.
The US Government has asked drugmakers and fine chemicals firms if laws designed to stop the proliferation of chemical weapons are hurting legitimate business.
Medidata has completed a method development project conducted in partnership with GlaxoSmithKline to evaluate the impact of combining mobile health (mHealth) devices with cloud-based technologies in a clinical trial.
How can a pharma company invest in continuous manufacturing without bleeding money when it retreats from a local market? Pfizer’s answer is production pods it can roll out anywhere in the world via helicopter… and pack away again if a market turns.
As questions continue to be raised over why Ricerca was on the brink of closure and laying off all of its employees, as well as how the company’s new owners and CEO plan to turn it around, one thing is certain: new CEO Clifford Croley is confident.
Dispatches from FT Global Pharmaceutical and Biotechnology conference, London
Vertical integration is inhibiting pharma R&D innovation, according to Quintiles CEO Tom Pike who says executives must be involved in selecting CROs.